Multidimensional Predictors for Neoadjuvant Chemotherapy Efficacy in Breast Cancer
DOI:
https://doi.org/10.53469/jcmp.2024.06(11).38Keywords:
Breast cancer, Neoadjuvant chemotherapy (NAC), Multidimensional predictorsAbstract
Breast cancer is one of the most common malignant tumors in women worldwide, and neoadjuvant chemotherapy (NAC) is an important treatment modality for locally advanced breast cancer. Predicting its efficacy has significant implications for guiding clinical treatment. This review aims to comprehensively explore the clinical applications and future prospects of multidimensional predictors in evaluating NAC efficacy in breast cancer. We will systematically analyze the characteristics, applications, and limitations of various predictors from clinical pathology, imaging, molecular biology, and liquid biopsy perspectives. Additionally, we will explore the combined application of predictors and their potential in individualized treatment, as well as discuss future development trends.
References
Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh, Scotland) 66, 15-23, doi:10.1016/j.breast.2022.08.010 (2022).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians 71, 209-249, doi:10.3322/caac.21660 (2021).
Key, T. J., Verkasalo, P. K. & Banks, E. Epidemiology of breast cancer. The Lancet. Oncology 2, 133-140, doi:10.1016/s1470-2045(00)00254-0 (2001).
家庭医学月刊, 陈. J. 女性健康的"头号杀手"——乳腺癌. 34-37 (2015).
老人世界, 吕. J. 靠"自摸"早期诊断乳腺癌——一个需彻底摒弃的错误检测观念. 1 (2010).
柳镇, 王子雷, 刘慧翔 & 药物与人, 戚. J. 关注女性健康 远离乳腺癌! , 3 (2008).
王子扬 & 自我保健, 董. J. 预防乳癌女性自己是第一责任人 高危人群半年一次专业检查,每天乳房自查. 2 (2013).
《中国乳腺癌新辅助治疗专家共识》专家组 & 中国癌症杂志, 邵. J. 中国乳腺癌新辅助治疗专家共识(2022年版). 32, 9 (2022).
Spring, L. et al. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN 15, 1216-1223, doi:10.6004/jnccn.2017.0158 (2017).
Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England) 384, 164-172, doi:10.1016/s0140-6736(13)62422-8 (2014).
Zhang, X. et al. Integrated single-cell and bulk RNA sequencing analysis identifies a neoadjuvant chemotherapy-related gene signature for predicting survival and therapy in breast cancer. BMC medical genomics 16, 300, doi:10.1186/s12920-023-01727-0 (2023).
Xu, W. et al. Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review. OncoTargets and therapy 13, 5887-5899, doi:10.2147/ott.S253056 (2020).
Peng, Y. et al. Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer biology & therapy 21, 189-196, doi:10.1080/15384047.2019.1680057 (2020).
Wang, M., Wei, Z., Kong, J. & Zhao, H. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients. Diagnostic pathology 19, 53, doi:10.1186/s13000-024-01451-y (2024).
Lu, M. et al.
Antunovic, L. et al. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy. European journal of nuclear medicine and molecular imaging 46, 1468-1477, doi:10.1007/s00259-019-04313-8 (2019).
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752, doi:10.1038/35021093 (2000).
Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98, 10869-10874, doi:10.1073/pnas.191367098 (2001).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine 344, 783-792, doi:10.1056/nejm200103153441101 (2001).
Bryce, J., Bauer, M. & Hadji, P. Managing arthralgia in a postmenopausal woman taking an aromatase inhibitor for hormonesensitive early breast cancer: a case study. Cancer management and research 4, 105-111, doi:10.2147/cmar.S29448 (2012).
Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell research 31, 178-186, doi:10.1038/s41422-020-0375-9 (2021).
Symmans, W. F. et al. Genomic index of sensitivity to endocrine therapy for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28, 4111-4119, doi:10.1200/jco.2010.28.4273 (2010).
Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 31, 3997-4013, doi:10.1200/jco.2013.50.9984 (2013).
de Azambuja, E. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British journal of cancer 96, 1504-1513, doi:10.1038/sj.bjc.6603756 (2007).
Penault-Llorca, F. et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, 2809-2815, doi:10.1200/jco.2008.18.2808 (2009).
Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC scientific publications, 247-270 (2004).
Kandioler-Eckersberger, D. et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 6, 50-56 (2000).
Tung, N. et al. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38, 1539-1548, doi:10.1200/jco.19.03292 (2020).
Byrski, T. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast cancer research and treatment 147, 401-405, doi:10.1007/s10549-014-3100-x (2014).
Callagy, G. M. et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 2468-2475, doi:10.1158/1078-0432.Ccr-05-2719 (2006).
Ameh-Mensah, C. et al. The Analysis of bcl-2 in Association with p53 and Ki-67 in Triple Negative Breast Cancer and Other Molecular Subtypes in Ghana. Journal of oncology 2021, 7054134, doi:10.1155/2021/7054134 (2021).
Tanner, M. et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24, 2428-2436, doi:10.1200/jco.2005.02.9264 (2006).
Di Leo, A. et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clinical cancer research : an official journal of the American Association for Cancer Research 8, 1107-1116 (2002).
Mann, R. M. et al. Breast MRI: EUSOBI recommendations for women's information. European radiology 25, 3669-3678, doi:10.1007/s00330-015-3807-z (2015).
Schaefgen, B. et al. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? Annals of surgical oncology 23, 789-795, doi:10.1245/s10434-015-4918-0 (2016).
Gutman, D. A. et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267, 560-569, doi:10.1148/radiol.13120118 (2013).
Ji, F. et al. Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures. Frontiers in molecular biosciences 8, 759495, doi:10.3389/fmolb.2021.759495 (2021).
Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nature immunology 14, 1014-1022, doi:10.1038/ni.2703 (2013).
Jabeen, S. et al. Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics. Oncoimmunology 8, e1537691, doi:10.1080/2162402x.2018.1537691 (2019).
Garner, H. & de Visser, K. E. Immune crosstalk in cancer progression and metastatic spread: a complex conversation. Nature reviews. Immunology 20, 483-497, doi:10.1038/s41577-019-0271-z (2020).
Fu, X. L. et al. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer immunology, immunotherapy : CII 66, 1597-1608, doi:10.1007/s00262-017-2052-5 (2017).
Gupta, N., Goswami, B. & Mittal, P. Effect of standard anthracycline based neoadjuvant chemotherapy on circulating levels of serum IL-6 in patients of locally advanced carcinoma breast - a prospective study. International journal of surgery (London, England) 10, 638-640, doi:10.1016/j.ijsu.2012.11.007 (2012).
Mittal, S. K. & Roche, P. A. Suppression of antigen presentation by IL-10. Current opinion in immunology 34, 22-27, doi:10.1016/j.coi.2014.12.009 (2015).
De Santo, C. et al. Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nature immunology 11, 1039-1046, doi:10.1038/ni.1942 (2010).
Valdés-Ferrada, J. et al. Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients. Frontiers in immunology 11, 1413, doi:10.3389/fimmu.2020.01413 (2020).
Jin, L. et al. Expression of interleukin-1beta in human breast carcinoma. Cancer 80, 421-434, doi:10.1002/(sici)1097-0142(19970801)80:3<421::aid-cncr10>3.0.co;2-z (1997).
Berry, K. K. et al. Expression of interleukin-8 in human metastatic endometrial carcinoma cells and its regulation by inflammatory cytokines. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 11, 54-60, doi:10.1046/j.1525-1438.2001.011001054.x (2001).
山东医药, 钟. J. 乳腺癌患者血浆IL-6,IL-8,TNF-α水平变化及其临床意义. 56, 82-84 (2016).
胡金华, 张耀晴 & 现代肿瘤医学, 朱. J. 乳腺癌患者血清VEGF、TNF-α和IL-6的表达与预后的相关分析. (2015).
Lenardo, M. J. Fas and the art of lymphocyte maintenance. The Journal of experimental medicine 183, 721-724, doi:10.1084/jem.183.3.721 (1996).
Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nature reviews. Immunology 12, 180-190, doi:10.1038/nri3156 (2012).
Lee, S. & Margolin, K. Cytokines in cancer immunotherapy. Cancers 3, 3856-3893, doi:10.3390/cancers3043856 (2011).
Nocera, N. F., Lee, M. C., De La Cruz, L. M., Rosemblit, C. & Czerniecki, B. J. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Frontiers in pharmacology 7, 356, doi:10.3389/fphar.2016.00356 (2016).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Qiuyan Luo, Shengchun Liu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
